(Q44448546)

3 December 2017

title

Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine (English)

1 reference

3 December 2017

1

Dorothy K Hatsukami

1 reference

3 December 2017

Joni Jensen

2

1 reference

3 December 2017

Lisa H Brauer

3

1 reference

3 December 2017

Marc Mooney

4

1 reference

3 December 2017

Susan Schulte

5

1 reference

3 December 2017

Mehmet Sofuoglu

6

1 reference

3 December 2017

Paul R Pentel

7

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

Pharmacology, Biochemistry and Behavior

3 December 2017

published in

1 reference

3 December 2017

volume

75

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

1-7

1 reference

Sites and mechanisms for nicotine's action in the brain

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Behavioural pharmacology of 5-HT3 receptor ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

The in vitro effects of nicotine and cotinine on prostacyclin and thromboxane biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MDL 72222.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

The psychopharmacology of 5-HT3 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Safety of cotinine in humans: physiologic, subjective, and cognitive effects

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Effects of cotinine on cigarette self-administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Cotinine: effects with and without nicotine.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Signs and symptoms of tobacco withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Errors in using tobacco withdrawal scale

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Pharmacodynamic effects of cotinine in abstinent cigarette smokers.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Isolation and microsequencing of a novel cotinine receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Ondansetron Clinical Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Selective genotyping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 receptors and the serotonin transporter in the level of response to alcohol: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Attenuation of mecamylamine-precipitated nicotine-withdrawal aversion by the 5-HT3 receptor antagonist ondansetron.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

The development and initial validation of a questionnaire on smoking urges

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Randomised controlled trial of ondansetron in smoking cessation

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

Effects of 5-hydroxytryptamine3 antagonist, ondansetron, on cigarette smoking, smoke exposure, and mood in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0091-3057%2803%2900035-2

7 January 2021

10.1016/S0091-3057(03)00035-2

Identifiers

DOI

1 reference

3 December 2017

1 reference